Product
TCD601
Aliases
siplizumab
8 clinical trials
6 indications
Indication
Kidney TransplantIndication
Liver TransplantIndication
Diabetes MellitusIndication
Type 1Indication
kidney transplantIndication
Amyotrophic Lateral Sclerosis (ALS)Clinical trial
A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in de Novo Living Donor Renal TransplantationStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant RecipientsStatus: Completed, Estimated PCD: 2023-10-03
Clinical trial
A 60 Month, Single-arm, Proof-of-concept Study to Induce Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients Using Siplizumab, an Anti-CD2 Antibody in Combination With Cyclophosphamide and SplenectomyStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in de Novo Living Donor Renal TransplantationStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A 12-month, Randomized, Single-blind, Placebo-controlled Exposure-response Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (STRIDE)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant RecipientsStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)Status: Recruiting, Estimated PCD: 2026-11-01